Tetracyclic derivatives, their compositions and methods
Novel quinazoline derivatives provide a potent and selective solution to inhibit KRas(G12D), addressing the lack of effective KRas inhibitors for cancer treatment by modulating KRas activity and reducing tumor growth.
JP2026530466APending Publication Date: 2026-09-08ENSEM THERAPEUTICS INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2026512658
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-31
- Filing Date
- 2024-08-23
- Publication Date
- 2026-09-08
AI Technical Summary
Technical Problem
Current KRas(G12D) inhibitors have not been clinically demonstrated to be sufficiently safe and effective for cancer treatment, highlighting the urgent need for potent and selective inhibitors to target KRas mutations in various types of cancer.
Method used
Development of novel quinazoline derivatives that selectively target and inhibit KRas(G12D), exhibiting advantageous potency and selectivity profiles, suitable for oral administration as therapeutic agents.
Benefits of technology
The novel compounds effectively inhibit KRas(G12D) activity, providing a potential treatment for KRas-related cancers by negatively modulating cell proliferation and reducing tumor growth.
✦ Generated by Eureka AI based on patent content.
Abstract
This invention provides novel tetracyclic compounds and their derivatives, as well as pharmaceutical compositions thereof, and methods for treating various types of diseases and disorders, including cancer.
Need to check novelty before this filing date? Find Prior Art